Category Archives: Client News

UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting on May 21, 2018 Submission of UGN-101 New … Continue reading


Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence

NEW YORK, May 15, 2018 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Michael G. King, Jr. has been appointed Entrepreneur in Residence. Mr. King will … Continue reading


Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

Interim Analysis for Phase 3 HONOR study of Tonmya® in Military-Related PTSD Expected in Third Quarter of 2018 NEW YORK, May 14, 2018 — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to … Continue reading


Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

NEW YORK, May 10, 2018  — Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights … Continue reading


Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

NEW YORK, May 10, 2018 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial results and recent corporate highlights for the first quarter ended March 31, … Continue reading


Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development

NEW YORK, May 09, 2018  — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Stephanie Noviello, MD, MPH has joined the Company as Vice President, Clinical Development.  She will report to … Continue reading


UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May 08, 2018 — UroGen Pharma Ltd. (URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018, prior to the … Continue reading


Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention

NEW YORK, May 07, 2018 — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that it will present at the … Continue reading


TG Therapeutics, Inc. to Host Conference Call on First Quarter 2018 Financial Results and Business Update

NEW YORK, May 04, 2018 — TG Therapeutics, Inc. (TGTX), today announced that a conference call will be held on Tuesday, May 8, 2018 at 8:30am ET to discuss results for the first quarter of 2018 and provide a business … Continue reading


Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

NEW YORK, May 03, 2018 — Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2018. “We … Continue reading


Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy

Iclaprim met the primary endpoint Iclaprim was well tolerated in the study, with no nephrotoxicity observed Additional data from the previously announced results are included in the publication NEW YORK, May 01, 2018 — Motif Bio plc (MTFB.L) (MTFB), a … Continue reading


Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease

NEW YORK, May 01, 2018 — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to support the initiation of a Phase 2, potential pivotal efficacy study … Continue reading


TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, April 18, 2018 — TG Therapeutics, Inc. (TGTX), today announced preclinical data for TG-1601, the Company’s novel BET inhibitor at the American Association for Cancer Research (AACR) annual meeting, taking place this week in Chicago, Illinois, at McCormick … Continue reading


Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting

NEW YORK, April 18, 2018  — Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, announced that preclinical data supporting the clinical development of … Continue reading


Posting of UK Annual Report and Accounts & Notice of AGM

NEW YORK, April 17, 2018  — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted … Continue reading


Motif Bio Reports Fiscal Year 2017 Results

NEW YORK, April 10, 2018 — Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2017. Dr. Graham Lumsden, Chief Executive Officer, said:  “Motif Bio made tremendous … Continue reading


Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

First 50 Percent of Participants Enrolled in Phase 3 HONOR Study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Military-Related PTSD Interim Results of HONOR Study Expected in Third Quarter 2018 NEW YORK, April 04, 2018  — Tonix Pharmaceuticals … Continue reading


Mustang Bio to Present at Biotech Innovations Conference

NEW YORK, April 04, 2018  — Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today announced that Sadik Kassim, Ph.D., … Continue reading


UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

RA’ANANA, Israel and NEW YORK, April 03, 2018  — UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data presentation from … Continue reading


Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

Phase 3 HONOR Study Enrollment Continues and Interim Results of the First 50 Percent of Participants Expected in Third Quarter 2018 Topline Results of Approximately 550 Participants with Military-Related PTSD Expected in Fourth Quarter 2018 NEW YORK, April 03, 2018  … Continue reading